ArticleFrontiers in immunology2015
Killer B lymphocytes and their fas ligand positive exosomes as inducers of immune tolerance.
Article in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- How Effective are Exosomes in Overcoming Blood-Labyrinth Barrier in Sensorineural Hearing Loss? A Comprehensive Review of the Literature.International journal of nanomedicine · 2026Review
- Role of Seminal Exosomes in Reproduction.Journal of cellular physiology · 2025Review
- Extracellular Vesicles in Therapeutics: A Comprehensive Review on Applications, Challenges, and Clinical Progress.Pharmaceutics · 2024Review
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches.Journal of extracellular vesicles · 2024Article
- Noncanonical B Cells: Characteristics of Uncharacteristic B Cells.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Exosome Carrier Effects; Resistance to Digestion in Phagolysosomes May Assist Transfers to Targeted Cells; II Transfers of miRNAs Are Better Analyzed via Systems Approach as They Do Not Fit Conventional Reductionist Stoichiometric Concepts.International journal of molecular sciences · 2022Review
- Review
- Characterization and Activation of Fas Ligand-Producing Mouse B Cells and Their Killer Exosomes.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Dark-Side of Exosomes.Advances in experimental medicine and biology · 2021Article
- B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis.Frontiers in immunology · 2021Review
- Advances of Regulatory B Cells in Autoimmune Diseases.Frontiers in immunology · 2021Review
- Semen-Derived Exosomes Mediate Immune Escape and Transmission of Reticuloendotheliosis Virus.Frontiers in immunology · 2021Article
- Immunoglobulin profile and B-cell frequencies are altered with changes in the cellular microenvironment independent of the stimulation conditions.Immunity, inflammation and disease · 2020Article
- Review
- Role of exosomes in tumour and transplant immune regulation.Scandinavian journal of immunology · 2019Review
- Exosomes: Versatile Nano Mediators of Immune Regulation.Cancers · 2019Review
- Rapid On-Demand Extracellular Vesicle Augmentation with Versatile Oligonucleotide Tethers.ACS nano · 2019Article
- Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.Experimental & molecular medicine · 2019Article
- Roles of Exosomes Derived From Immune Cells in Cardiovascular Diseases.Frontiers in immunology · 2019Review
- CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.JCI insight · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Induction of immune tolerance is a key process by which the immune system is educated to modulate reactions against benign stimuli such as self-antigens and commensal microbes. Understanding and harnessing the natural mechanisms of immune tolerance may become an increasingly useful strategy for treating many types of allergic and autoimmune diseases, as well as for improving the acceptance of solid organ transplants. Our laboratory and others have been interested in the natural ability of some B lymphocytes to express the death-inducing molecule Fas ligand (FasL), and their ability to kill T helper (TH) lymphocytes. We have recently shown that experimental transformation of human B cells by a non-replicative variant of Epstein-Barr virus (EBV) consistently resulted in high expression of functional FasL protein. The production and release of FasL(+) exosomes that co-expressed major histocompatibility complex (MHC) class II molecules and had the capacity to kill antigen-specific TH cells was also observed. Several lines of evidence indicate that FasL+ B cells and FasL(+)MHCII(+) exosomes have important roles in natural immune tolerance and have a great deal of therapeutic potential. Taken together, these findings suggest that EBV-immortalized human B lymphoblastoid cell lines could be used as cellular factories for FasL(+) exosomes, which would be employed to therapeutically establish and/or regain immune tolerance toward specific antigens. The goals of this review are to summarize current knowledge of the roles of FasL(+) B cells and exosomes in immune regulation, and to suggest methods of manipulating killer B cells and FasL(+) exosomes for clinical purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.